Medical Cannabis Use Patterns for Sleep Disorders in Australia: Results of the Cross-Sectional CAMS-20 Survey

References

• Ramar K, Malhotra RK, Carden KA, et al. Sleep is essential to health: an American Academy of Sleep Medicine position statement. J Clin Sleep Med. 2021;17(10):2115–2119.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wheaton AG, Chapman DP, et al. Prevalence of healthy sleep duration among adults—United States, 2014. Morb Mortal Wkly Rep. 2016;65((6)):137–141.
   PubMed Web of Science ®Google Scholar
• Baglioni C, Altena E, Bjorvatn B, et al. The European Academy for Cognitive Behavioural Therapy for Insomnia: an initiative of the European Insomnia Network to promote implementation and dissemination of treatment. J Sleep Res. 2020;29((2)):e12967.
   PubMed Web of Science ®Google Scholar
• De Crescenzo F, D’Alò GL, Ostinelli EG, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400(10347):170–184.
   PubMed Web of Science ®Google Scholar
• Bachhuber M, Arnsten JH, Wurm G. Use of cannabis to relieve pain and promote sleep by customers at an adult use dispensary. J Psychoactive Drugs. 2019;51((5)):400–404.
   PubMed Web of Science ®Google Scholar
• Piper BJ, DeKeuster RM, Beals ML, et al. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol. 2017;31((5)):569–575.
   PubMed Web of Science ®Google Scholar
• Lintzeris NDJ, Elias N, Arnold JC, McGregor IS, Allsop DJ. Findings from the Cannabis as Medicine Survey (CAMS-16): an online survey of medical cannabis use in Australia. Med J Aust. 2018;209:211–216.
   PubMed Web of Science ®Google Scholar
• Lintzeris N, Mills L, Suraev A, et al. Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduct J. 2020;2020:1–12.
   Google Scholar
• Lintzeris N, Mills L, Abelev SV, et al. Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20). Harm Reduct J. 2022;19((1)):1–10.
   PubMed Web of Science ®Google Scholar
• MacPhail S, Bedoya-Perez MA, Cohen R, et al. Medicinal cannabis prescribing in Australia: an analysis of trends over the first five years. Front Pharmacol. 2022;13:1368.
   Web of Science ®Google Scholar
• Cahill SP, Lunn SE, Diaz P, et al. Evaluation of patient reported safety and efficacy of cannabis from a survey of medical cannabis patients in Canada. Front Public Health. 2021;9:1.
   Web of Science ®Google Scholar
• Suraev AS, Marshall NS, Vandrey R, et al. Cannabinoid therapies in the management of sleep disorders: a systematic review of preclinical and clinical studies. Sleep Med Rev. 2020;53:101339.
   PubMed Web of Science ®Google Scholar
• AminiLari M, Wang L, Neumark S, et al. Medical cannabis and cannabinoids for impaired sleep: a systematic review and meta-analysis of randomized clinical trials. Sleep. 2022;45(2):zsab234.
   PubMed Web of Science ®Google Scholar
• Walsh JH, Maddison KJ, Rankin T, et al. Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo. Sleep. 2021;44(11):zsab149.
   PubMed Web of Science ®Google Scholar
• Australian New Zealand Clinical Trials Registry. A phase IIb double-blind, randomised placebo-controlled clinical trial to evaluate the efficacy and safety of a botanical cannabidiol (CBD) for sleep disturbances in a healthy population. ACTRN12621000632897. Sydney (NSW): NHMRC Clinical Trials Centre, University of Sydney (Australia). Available from: https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12621000632897. Accessed September 19, 2022.
   Google Scholar
• National Institutes of Health Clinical Center. The Cannabidiol use for relief of short term insomnia (CANREST). NCT05253417. National Institutes of Health; 2022. Available from: ClinicalTrials.gov. Accessed September 19, 2022.
   Google Scholar
• Australian New Zealand Clinical Trials Registry. Cannabidiol (CBD) treatment for insomnia. ACTRN12620000070932. Sydney (NSW): NHMRC Clinical Trials Centre, University of Sydney (Australia). Available from: https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12620000070932. Accessed September 19, 2022.
   Google Scholar
• National Institutes of Health Clinical Center. Evaluation of an oral cannabidiol (CBD)-terpene formulation on sleep physiology in participants with insomnia. NCT05233761. National Institutes of Health; 2022. Available from: ClinicalTrials.gov. Accessed September 19, 2022.
   Google Scholar
• Australian New Zealand Clinical Trials Registry. A single-dose, double-blind, placebocontrolled, randomised, crossover study of an oral cannabis-based medicine (ETC120) on sleep, cognition, and next-day function in adults with chronic insomnia disorder. ACTRN12619000714189. Sydney (NSW): NHMRC Clinical Trials Centre, University of Sydney; 2020.
   Google Scholar
• Calik MW, Carley DW. Intracerebroventricular injections of dronabinol, a cannabinoid receptor agonist, does not attenuate serotonin-induced apnea in Sprague-Dawley rats. J Negat Res Biomed. 2016;15:1–7.
   PubMedGoogle Scholar
• Calik MW, Carley DW. Cannabinoid type 1 and type 2 receptor antagonists prevent attenuation of serotonin-induced reflex apneas by dronabinol in Sprague-Dawley rats. PLoS One. 2014;9(10):e111412.
   PubMed Web of Science ®Google Scholar
• Calik MW, Carley DW. Effects of cannabinoid agonists and antagonists on sleep and breathing in Sprague-Dawley rats. Sleep. 2017;40:9.
   Web of Science ®Google Scholar
• Carley DW, Pavlovic S, Janelidze M, et al. Functional role for cannabinoids in respiratory stability during sleep. Sleep. 2002;25(4):388–395.
   Web of Science ®Google Scholar
• Carley DW, Prasad B, Reid KJ, et al. Pharmacotherapy of apnea by cannabimimetic enhancement, the PACE clinical trial: effects of dronabinol in obstructive sleep apnea. Sleep. 2018;41:1.
   Web of Science ®Google Scholar
• Prasad B, Radulovacki MG, Carley DW. Proof of concept trial of dronabinol in obstructive sleep apnea. Front Psychiatry. 2013;4:1.
   PubMedGoogle Scholar
• Australian New Zealand Clinical Trials Registry. Proof of concept study on the combined effect of dronabinol and Acetazolamide on apnoea hypopnoea index (AHI) in adults with obstructive sleep apnoea. ACTRN12620000916943. Sydney (NSW): NHMRC Clinical Trials Centre, University of Sydney (Australia). Available from: https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12620000916943. Accessed September 19, 2022.
   Google Scholar
• Megelin R, Ghorayeb I. Cannabis for restless legs syndrome: a report of six patients. Sleep Med. 2017;36:182e83.
   Web of Science ®Google Scholar
• Ghorayeb I. More evidence of cannabis efficacy in restless legs syndrome. Sleep Breath. 2020;24(1):277–279.
   PubMed Web of Science ®Google Scholar
• Lavender I, McGregor IS, Suraev A, et al. Cannabinoids, insomnia, and other sleep disorders. CHEST. 2022;162(2):452–465.
   PubMed Web of Science ®Google Scholar
• Arnold JC, Nation T, McGregor IS. Prescribing medicinal cannabis. Aust Prescr. 2020;43(5):152.
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381.
   PubMed Web of Science ®Google Scholar
• Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004;27((1)):26–35.
   PubMed Web of Science ®Google Scholar
• Beasley TM, Schumacker RE. Multiple regression approach to analyzing contingency tables: post hoc and planned comparison procedures. J Exp Educ. 1995;64(1):79–93.
   Web of Science ®Google Scholar
• Spindle TR, Martin EL, Grabenauer M, et al. Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis. J Psychopharmacol. 2021;35(7):786–803.
   PubMed Web of Science ®Google Scholar
• Spindle TR, Cone EJ, Schlienz NJ, et al. Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial. JAMA Netw Open. 2018;1(7):e184841–e41.
   PubMed Web of Science ®Google Scholar
• Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770.
   PubMed Web of Science ®Google Scholar
• Schlienz NJ, Spindle TR, Cone EJ, et al. Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis. Drug Alcohol Depend. 2020;211:107969.
   PubMed Web of Science ®Google Scholar
• Perucca E, Bialer M. Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications. CNS Drugs. 2020;34(8):795–800.
   PubMed Web of Science ®Google Scholar
• MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–19.
   PubMed Web of Science ®Google Scholar
• Ghasemiesfe M, Ravi D, Vali M, et al. Marijuana use, respiratory symptoms, and pulmonary function: a systematic review and meta-analysis. Ann Intern Med. 2018;169(2):106–115.
   PubMed Web of Science ®Google Scholar
• Haack M, Simpson N, Sethna N, et al. Sleep deficiency and chronic pain: potential underlying mechanisms and clinical implications. Neuropsychopharmacology. 2020;45(1):205–216.
   PubMed Web of Science ®Google Scholar
• Freeman D, Sheaves B, Waite F, et al. Sleep disturbance and psychiatric disorders. Lancet Psychiat. 2020;7(7):628–637.
   PubMed Web of Science ®Google Scholar
• Bjorvatn B, Jernelöv S, Pallesen S. Insomnia–a heterogenic disorder often comorbid with psychological and somatic disorders and diseases: a narrative review with focus on diagnostic and treatment challenges. Front Psychol. 2021;289:1.
   Google Scholar
• Husak AJ, Bair MJ. Chronic pain and sleep disturbances: a pragmatic review of their relationships, comorbidities, and treatments. Pain Med. 2020;21(6):1142–1152.
   PubMed Web of Science ®Google Scholar
• Franzen PL, Buysse DJ. Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. Dialogues Clin Neurosci. 2022;10(4):473–481.
   Google Scholar
• Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex®, a cannabis‐based medicine. Chem Biodivers. 2007;4(8):1729–1743.
   PubMed Web of Science ®Google Scholar
• Meyer T, Funke A, Münch C, et al. Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol: cannabidiol (THC: CBD). BMC Neurol. 2019;19:1–13.
   PubMed Web of Science ®Google Scholar
• Grimison P, Mersiades A, Kirby A, et al. Oral THC: CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, Phase II crossover trial. Ann Oncol. 2020;31(11):1553–1560.
   PubMed Web of Science ®Google Scholar
• Osborne GB, Fogel C. Understanding the motivations for recreational marijuana use among adult Canadians. Subst Use Misuse. 2008;43(3–4):539–572.
   PubMed Web of Science ®Google Scholar
• Blessing EM, Steenkamp MM, Manzanares J, et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825–836.
   PubMed Web of Science ®Google Scholar
• Carney CE, Harris AL, Falco A, et al. The relation between insomnia symptoms, mood, and rumination about insomnia symptoms. J Clin Sleep Med. 2013;9(6):567–575.
   PubMed Web of Science ®Google Scholar
• Lucas P, Boyd S, Milloy M-J, et al. Cannabis significantly reduces the use of prescription opioids and improves quality of life in authorized patients: results of a large prospective study. Pain Med. 2021;22(3):727–739.
   PubMed Web of Science ®Google Scholar
• Gates PJ, Albertella L, Copeland J. The effects of cannabinoid administration on sleep: a systematic review of human studies. Sleep Med Rev. 2014;18(6):477–487.
   PubMed Web of Science ®Google Scholar
• Allsop D, Norberg MM, Copeland J, et al. The cannabis withdrawal scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend. 2011;119:123–129.
   PubMed Web of Science ®Google Scholar
• Vandrey R, Smith MT, McCann UD, et al. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug Alcohol Depend. 2011;117(1):38–44.
   PubMed Web of Science ®Google Scholar
• Mills L, Lintzeris N, O’Malley M, et al. Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. Drug Alcohol Rev. 2022;41(5):1095–1108.
   PubMed Web of Science ®Google Scholar
• Babson KA, Boden MT, Harris AH, et al. Poor sleep quality as a risk factor for lapse following a cannabis quit attempt. J Subst Abuse Treat. 2013;44(4):438–443.
   PubMed Web of Science ®Google Scholar
• Suraev A, Benson MJ, Martin L, et al. Determination of contaminants in artisanal cannabis products used for childhood epilepsy in the Australian community: a sub-analysis of the ‘PELICAN’ study. Epilepsy Behav. 2022;127:108496.
   PubMed Web of Science ®Google Scholar